BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16087939)

  • 1. Self-recognition and tumor response to immunotherapy.
    Ernstoff MS
    J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunotherapy for melanoma: how can tolerance be overcome?].
    Robert C
    Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell recognition efficiency by T cells.
    Speiser DE; Cerottini JC; Romero P
    PLoS Med; 2005 Mar; 2(3):e77; author reply e95. PubMed ID: 15783261
    [No Abstract]   [Full Text] [Related]  

  • 7. [Active specific immunotherapy of malignant melanoma].
    Lotem M; Shiloni E; Ingber A; Peretz T
    Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
    [No Abstract]   [Full Text] [Related]  

  • 8. The unfulfilled promise of melanoma vaccines.
    Livingston P
    Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
    Marincola FM; Ferrone S
    Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of melanoma.
    Chapman PB
    Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
    [No Abstract]   [Full Text] [Related]  

  • 13. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and induced human antibody response to cancer.
    Lake DF; Huynh WC; Hersh EM
    Cancer Invest; 2000; 18(5):480-9. PubMed ID: 10834032
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of immunotherapy in the treatment of melanoma.
    Faries MB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
    Lejeune FJ
    Melanoma Res; 2006 Oct; 16(5):377-8. PubMed ID: 17013085
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.